retatrutide phase 2 trial type 2 diabetes results 2024 Lilly's triple agonist delivers up to 71.2 lbs of weight loss retatrutide phase 2 trial type

GLP-1 receptor agonists have emerged as a major advancement, offering clinically meaningful and sustained weight loss alongside improvements in glycemic control and cardiovascular outcomes

There are restrictions to the availability of this data, which is used under license for this study

backup contraception may be advisable Injection site reactions : Erythema, pruritus, or nodules may occur with subcutaneous administration For dietary supplements marketed as "keto all-in-one GLP-1" products, safety concerns differ substantially

Tirzepatide is an approved GLP-1R/GIP dual agonist developed by Eli Lilly, garnering significant attention alongside SEMA in the field of T2DM and weight loss